Cargando…
Combining immune checkpoint blockade with ATP-based immunogenic cell death amplifier for cancer chemo-immunotherapy
Amplifying “eat me signal” during tumor immunogenic cell death (ICD) cascade is crucial for tumor immunotherapy. Inspired by the indispensable role of adenosine triphosphate (ATP, a necessary “eat me signal” for ICD), a versatile ICD amplifier was developed for chemotherapy-sensitized immunotherapy....
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9513492/ https://www.ncbi.nlm.nih.gov/pubmed/36176905 http://dx.doi.org/10.1016/j.apsb.2022.05.008 |
_version_ | 1784798076759703552 |
---|---|
author | Zhang, Jiulong Sun, Xiaoyan Zhao, Xiufeng Yang, Chunrong Shi, Menghao Zhang, Benzhuo Hu, Haiyang Qiao, Mingxi Chen, Dawei Zhao, Xiuli |
author_facet | Zhang, Jiulong Sun, Xiaoyan Zhao, Xiufeng Yang, Chunrong Shi, Menghao Zhang, Benzhuo Hu, Haiyang Qiao, Mingxi Chen, Dawei Zhao, Xiuli |
author_sort | Zhang, Jiulong |
collection | PubMed |
description | Amplifying “eat me signal” during tumor immunogenic cell death (ICD) cascade is crucial for tumor immunotherapy. Inspired by the indispensable role of adenosine triphosphate (ATP, a necessary “eat me signal” for ICD), a versatile ICD amplifier was developed for chemotherapy-sensitized immunotherapy. Doxorubicin (DOX), ATP and ferrous ions (Fe(2+)) were co-assembled into nanosized amplifier (ADO-Fe) through π‒π stacking and coordination effect. Meanwhile, phenylboric acid-polyethylene glycol-phenylboric acid (PBA-PEG-PBA) was modified on the surface of ADO-Fe (denoted as PADO-Fe) by the virtue of d-ribose unit of ATP. PADO-Fe could display active targetability against tumor cells via sialic acid/PBA interaction. In acidic microenvironment, PBA-PEG-PBA would dissociate from amplifier. Moreover, high H(2)O(2) concentration would induce hydroxyl radical (·OH) and oxygen (O(2)) generation through Fenton reaction by Fe(2+). DOX and ATP would be released from the amplifier, which could induce ICD effect and “ICD adjuvant” to amplify this process. Together with programmed death ligands 1 (PD-L1) checkpoint blockade immunotherapy, PADO-Fe could not only activate immune response against primary tumor, but also strong abscopal effect against distant tumor. Our simple and multifunctional ICD amplifier opens a new window for enhancing ICD effect and immune checkpoint blockade therapy. |
format | Online Article Text |
id | pubmed-9513492 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-95134922022-09-28 Combining immune checkpoint blockade with ATP-based immunogenic cell death amplifier for cancer chemo-immunotherapy Zhang, Jiulong Sun, Xiaoyan Zhao, Xiufeng Yang, Chunrong Shi, Menghao Zhang, Benzhuo Hu, Haiyang Qiao, Mingxi Chen, Dawei Zhao, Xiuli Acta Pharm Sin B Original Article Amplifying “eat me signal” during tumor immunogenic cell death (ICD) cascade is crucial for tumor immunotherapy. Inspired by the indispensable role of adenosine triphosphate (ATP, a necessary “eat me signal” for ICD), a versatile ICD amplifier was developed for chemotherapy-sensitized immunotherapy. Doxorubicin (DOX), ATP and ferrous ions (Fe(2+)) were co-assembled into nanosized amplifier (ADO-Fe) through π‒π stacking and coordination effect. Meanwhile, phenylboric acid-polyethylene glycol-phenylboric acid (PBA-PEG-PBA) was modified on the surface of ADO-Fe (denoted as PADO-Fe) by the virtue of d-ribose unit of ATP. PADO-Fe could display active targetability against tumor cells via sialic acid/PBA interaction. In acidic microenvironment, PBA-PEG-PBA would dissociate from amplifier. Moreover, high H(2)O(2) concentration would induce hydroxyl radical (·OH) and oxygen (O(2)) generation through Fenton reaction by Fe(2+). DOX and ATP would be released from the amplifier, which could induce ICD effect and “ICD adjuvant” to amplify this process. Together with programmed death ligands 1 (PD-L1) checkpoint blockade immunotherapy, PADO-Fe could not only activate immune response against primary tumor, but also strong abscopal effect against distant tumor. Our simple and multifunctional ICD amplifier opens a new window for enhancing ICD effect and immune checkpoint blockade therapy. Elsevier 2022-09 2022-05-16 /pmc/articles/PMC9513492/ /pubmed/36176905 http://dx.doi.org/10.1016/j.apsb.2022.05.008 Text en © 2022 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Article Zhang, Jiulong Sun, Xiaoyan Zhao, Xiufeng Yang, Chunrong Shi, Menghao Zhang, Benzhuo Hu, Haiyang Qiao, Mingxi Chen, Dawei Zhao, Xiuli Combining immune checkpoint blockade with ATP-based immunogenic cell death amplifier for cancer chemo-immunotherapy |
title | Combining immune checkpoint blockade with ATP-based immunogenic cell death amplifier for cancer chemo-immunotherapy |
title_full | Combining immune checkpoint blockade with ATP-based immunogenic cell death amplifier for cancer chemo-immunotherapy |
title_fullStr | Combining immune checkpoint blockade with ATP-based immunogenic cell death amplifier for cancer chemo-immunotherapy |
title_full_unstemmed | Combining immune checkpoint blockade with ATP-based immunogenic cell death amplifier for cancer chemo-immunotherapy |
title_short | Combining immune checkpoint blockade with ATP-based immunogenic cell death amplifier for cancer chemo-immunotherapy |
title_sort | combining immune checkpoint blockade with atp-based immunogenic cell death amplifier for cancer chemo-immunotherapy |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9513492/ https://www.ncbi.nlm.nih.gov/pubmed/36176905 http://dx.doi.org/10.1016/j.apsb.2022.05.008 |
work_keys_str_mv | AT zhangjiulong combiningimmunecheckpointblockadewithatpbasedimmunogeniccelldeathamplifierforcancerchemoimmunotherapy AT sunxiaoyan combiningimmunecheckpointblockadewithatpbasedimmunogeniccelldeathamplifierforcancerchemoimmunotherapy AT zhaoxiufeng combiningimmunecheckpointblockadewithatpbasedimmunogeniccelldeathamplifierforcancerchemoimmunotherapy AT yangchunrong combiningimmunecheckpointblockadewithatpbasedimmunogeniccelldeathamplifierforcancerchemoimmunotherapy AT shimenghao combiningimmunecheckpointblockadewithatpbasedimmunogeniccelldeathamplifierforcancerchemoimmunotherapy AT zhangbenzhuo combiningimmunecheckpointblockadewithatpbasedimmunogeniccelldeathamplifierforcancerchemoimmunotherapy AT huhaiyang combiningimmunecheckpointblockadewithatpbasedimmunogeniccelldeathamplifierforcancerchemoimmunotherapy AT qiaomingxi combiningimmunecheckpointblockadewithatpbasedimmunogeniccelldeathamplifierforcancerchemoimmunotherapy AT chendawei combiningimmunecheckpointblockadewithatpbasedimmunogeniccelldeathamplifierforcancerchemoimmunotherapy AT zhaoxiuli combiningimmunecheckpointblockadewithatpbasedimmunogeniccelldeathamplifierforcancerchemoimmunotherapy |